Newly Rebranded Elumn8 Medical Secures Series C Financing

Elumn8 Medical Inc., formerly known as Simpson Interventions, has closed a Series C financing round that will help support continued development of the Acolyte Image-Guided Crossing and Re-Entry Catheter System. The solution is currently being evaluated in a pre-market clinical trial for treating coronary chronic total occlusions (CTOs)—a.k.a., completely blocked coronary arteries.

The rebrand reflects the company’s evolution and its focus on advancing image-enabled technologies that improve the precision, predictability, and safety of complex coronary interventions. It also references the eighth medical device company founded by Dr. John B. Simpson, whose seminal advancements in coronary and peripheral interventions have transformed interventional cardiology.

“We are excited to secure the initial close of our Series C financing and to introduce Elumn8 Medical as the next chapter in our company’s growth,” Elumn8 Medical CEO Joe Knight said. “This funding strengthens our ability to execute on our clinical and regulatory strategy. We are grateful to the investors who have demonstrated confidence in our vision for this therapeutic option.”

Enrollment continues in Elumn8 Medical’s Acolyte pre-market clinical trial, which is evaluating the safety and performance of the Acolyte Image-Guided Crossing and Re-Entry Catheter System in patients undergoing CTO percutaneous coronary intervention (CTO-PCI). Enrollment is taking place at multiple U.S. sites, with up to 103 patients expected across a maximum 15 centers.

“The progress we are seeing in the Acolyte clinical program reinforces our belief that image-guided CTO crossing and re-entry represents an important advancement for interventional cardiology,” stated Dr. Simpson, Elumn8 Medical’s founder and chief medical officer. “Further, I am thrilled by our rebranding to Elumn8 Medical, as it better captures our mission to visualize complex coronary anatomy and enable more consistent, minimally invasive treatment of CTOs.”

During coronary CTO procedures, the Acolyte System is designed to provide real-time intravascular imaging to support controlled guidewire true-lumen crossing and targeted re-entry into the correct channel for blood flow distal to the lesion, which remains a difficult technical challenge for interventional cardiologists. By integrating optical coherence tomography (OCT) imaging directly into a crossing and re-entry catheter, Acolyte aims to improve procedural efficiency, predictability, and safety by enabling wire delivery during concurrent fluoroscopy and OCT visualization.

The Acolyte System has received U.S. Food and Drug Administration Breakthrough Device Designation and has been accepted into the agency’s Total Product Life Cycle Advisory Program (TAP).

The Acolyte System in an investigational device limited by U.S. law to investigational use.

Elumn8 Medical is a medical technology firm advancing image-enabled solutions for complex coronary interventions. The company’s technologies are designed to enhance visualization, control, and procedural confidence in minimally invasive percutaneous treatments, with an initial focus on coronary chronic total occlusions.